Table 1: Guideline data collection

Size: px
Start display at page:

Download "Table 1: Guideline data collection"

Transcription

1 Table 1: Guideline data collection Guideline table Arguments Key Guideline number Numerical number to allocate the. Numerical number Filenames File name of the record. e.g. G0001.csv Guideline name Identity of the. Copy the name from the Guideline disease Disease where the s are made for. Copy the disease Name of the institution Guideline institution who wrote the. Copy the institution s name Category of the institution Category institution who wrote the. 0 = industry 1 = HTA 2 = NICE 3 = SIGN 4 = SIGN + other body 5 = professional body (e.g. RCPCH / BTS) 6 = NICE + other body 7 = other Funding Mentioned funder in the 0 = unclear, not mentioned 1 = industry 2 = government 3 = foundation 4 = other 5 = not externally funded Date of publication Date of publications Month and year of publication. E.g. Dec-11 Review date Date the is/will be reviewed 0 = unclear update time Review date in time in years after first publication. Update time mentioned in the Time period for the to be updated given in the. 0 = unclear update time Update time in years. Number of s Number of s made in the Number of s Number of s Number of s made in the Number of included s included which included in the research Methodology used in the Methodology used by the. Copy the used methodology URL For quick access to the. Copy the URL

2 Completeness of declarations of interest How complete the declarations of interest are. E.g. only mentioned that there is no conflict of interest or per person mentioned what the work functions are. Conflict of interest If there is a conflict of interest 0 = unknown 1 = yes 2 = no Grading Level of evidence per known Methodology used for grading the evidence used in the If the level of evidence per is given in the 5 = easy; in the 1 = not available 2 = unknown because difficult to access 3 = unspecified 4 = specified what conflicts are 5 = specified per person what all work functions are 0 = Unknown 1 = SIGN 2 = AHCPCR, = GRADE (Grading of Recommendations Assessment, Development and Evaluation system) 4 = HTA report 5 = Other 0 = Inapplicable 1 = Yes 2 = No Version

3 Table 2: Guideline data collection Guideline table Arguments Key Guideline name To identify the Copy the name from the master table of s. Guideline number To refer to the Copy the number from the master table of s Filenames File name of the e.g csv record. Number of s Number of s made in the Number of s Recommendation number Page of Paragraph of Recommendation Recommendation included Level of evidence. Numerical number to allocate the. To easily find the To easily find the Recommendation made in the e.g. s about diagnosing are excluded Use SIGN methodology to determine the reliability of the. Numerical number 0 = inapplicable Copy the page of Copy the paragraph of Copy the 0 = included 1 = excluded 0 = level of evidence unclear SIGN methodology 1++ = High quality meta-analyses, systemic reviews of RCTs, or RCTs with a very low risk of bias. 1+ = Well conducted meta-analyses, systemic reviews, or RCTs with a low risk of bias. 1- = Meta-analyses, systemic reviews, or RCTs with a low risk of bias. 2++ = High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal. 2+ = Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal. Version

4 2- = Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 = Non-analytical studies, eg case reports, case series 4 = Expert opinion Converting GRADE methodology to SIGN methodology: QoE (quality of evidence) GRADE methodology Converted to SIGN methodology High 1 Moderate 2 Low 3 Very low 4 Converting AHCPR methodology to SIGN methodology: Level of evidence AHCPR methodology A: Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific. B: Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of the. C: Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality. Converted to SIGN methodology Converting level of evidence used in the BTS : Guidelines for the management of community acquired pneumonia in children, to SIGN methodology: Level of evidence BTS methodology Converted to SIGN methodology A+: A good recent systematic review of studies designed to 1 2 answer the question of interest A-: One or more rigorous studies designed to answer the 2 question, but not formally combined B+: One or more prospective clinical studies which illuminate, 2 but do not rigourisly answer, the question B-: One or more retrospective clinical studies which illuminate, 2 but do not rigoursly answer, the question C: formal combination of expert views 4 D: other information 4 Version

5 Converting BTS methodology to SIGN methodology when using SIGN methodology but only given A/B/C/D: (s for non-cf bronchiectasis / RCPCH: standards for services for children with disorders of sleep/ RCPCH: A clinical for the management of children presenting with acute breathing difficulty Level of evidence BTS methodology Converted to SIGN methodology A B 1 2 C 2 D 3 4 Converting level of evidence of the BTS : management of opportunist mycobacterical infections, to SIGN methodology: Level of evidence BTS methodology A: Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific. B: Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of. C: Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities, but indicates absence of directly applicable studies of good quality. Converted to SIGN methodology Decision for the level of evidence Grades of s Who specified the level of evidence Use SIGN methodology to determine the reliability of the. 0 = level of evidence specified by the 1 = level of evidence specified by us 2 = level of evidence unclear 0 = grade of unclear SIGN methodology A = At least one meta-analysis, systematic review, or RCT rated as 1++,and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+,directly applicable to the target population, and demonstrating overall consistency of results. Version

6 B = A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+ C = A body of evidence including studies rated as 2+,directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++. D = Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+ Converting GRADE methodology to SIGN methodology: QoE (quality of evidence) GRADE methodology Converted to SIGN methodology High A/B Moderate C Low D Very low D Converting AHCPR methodology to SIGN methodology: Level of evidence AHCPR Converted to SIGN methodology methodology A A B B B C C D Converting BTS methodology to SIGN methodology: Level of evidence BTS methodology A+: A good recent systematic review of studies designed to answer the question of interest A-: One or more rigorous studies designed to answer the question, but not formally combined Converted to SIGN methodology A B B C B+: One or more prospective clinical studies which illuminate, but do not rigourisly B C answer, the question B-: One or more retrospective clinical studies which illuminate, but do not rigoursly B C answer, the question C: formal combination of expert views D D: other information D Version

7 Converting level of evidence of the BTS : management of opportunist mycobacterical infections, to SIGN methodology: Level of evidence BTS methodology A: Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific. B: Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of. C: Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities, but indicates absence of directly applicable studies of good quality. Converted to SIGN methodology A B B C D Decision for the grades of Patient s age Subcategory of patients/disease Who specified the level of evidence Age of the patients the is made for. Category of patients/disease. E.g. Acute asthma versus chronicle asthma. 0 = grade of specified by the 1 = grade of specified by us 2 = grade of unclear 0= inapplicable Age in years e.g Baby: 0-1 Neonate: 0-1/12 0 = inapplicable 1 = pregnant 2 = smoking 3 = symptomatic 4 = mild 5 = moderate 6 = severe 7 = life threatening 8 = breastfeeding 9 = other 10 = acute 11= chronic Version

8 Moment of therapy Type of intervention Effective intervention Specific medicine At which moment of therapy the intervention starts. Type of intervention. E.g. physiotherapy. If an intervention is effective or not Medicine recommended 12 = parents 0 = inapplicable 1 = starting 2= stepping up 3 = maintenance 4 = stepping down 5 = exacerbations 6 = continue 7 = add on 0 = avoidance 1 = nutritional/herbal 2 = exercise/physiotherapy 3 = prevention 4 = pharmacological 5 = surgical 6 = weight reduction 7 = quit smoking 8 = other 9 = supporting tool 10 = referral to specialist 11 = educational/informational 12 = psychotherapy 13 = hospitalisation 14 = type of device 0 = effective/recommended 1 = not effective/ not recommended 2 = intervention not more or less favoured over one other/insufficient evidence to make a choice 0= inapplicable Copy the name of the medicine recommended Version

9 Main group of the medicine Main group of the recommended medicine 0= inapplicable Copy the name and number of the main group of the medicine from the table. If the medicine is not mentioned in the table: put the name and number of the main group (See BNF for children) in the table and copy from the table. Main group of the medicine Number of the main group of the medicine Allergen immunotherapy Allergic emergencies Aminoglycosides Anaemias and some other blood disorders 9.1 Antibacterial drugs 5.1 Antifibrinolytic drugs and haemostatics 2.11 Antifungal drugs 5.2 Antihistamines Antimuscarinic bronchodilators Antituberculosis drugs Antiviral drugs 5.3 Bronchodilators 3.1 Cephalosporins, carbapenems, and other beta-lactams Compound bronchodilator preparations Corticosteroids 6.3 Cough suppresants Cromoglicate and related therapy Drugs used in nasal allergy Immunoglobulins 14.5 Inhaled corticosteroids 3.2 Leukotriene receptor antagonists Macrolides Magnesium Minerals 9.5 Mucolytics 3.7 Nasal preparations for infection Non-steroidal anti-inflammatory drugs Oral glucocorticoid therapy Oxygen 3.6 Version

10 Penicillins Proton pump inhibitors Quinolones Selective beta 2 agonists Skin cleansers, antiseptics, and preparations for promotion of wound healing Some other antibacterials Sulphonamides and trimethoprim Tetracyclines Theophylline Topical nasal decongestants Vaccines and antisera 14.4 Vitamins 9.6 Number of the main group of the medicine Dosage Date of literature search Title of Cochrane Review used Number of Cochrane Review used The main group recommended for intervention can be the same while the subgroup might differ. Total dose/day of the medicine for a stated amount of weight A might have different dates of literature search for different chapters. If a Cochrane review was used for the 0= inapplicable Copy the name and number of the main group of the medicine from the table (table can be found at main group of the medicine). If the medicine is not mentioned in the table: put the name and number of the main group (See BNF for children) in the table and copy from the table. 0= inapplicable Copy the total dose (mg)/day for a child of 20 kg s. 0 = date not clear Copy the date of literature search per. Title(s) of the used Cochrane reviews,, Number(s) of the title(s) of the Cochrane reviews. Version

11 Agreement between review and Agreement between the s in the Cochrane review and the. 0 = inapplicable 1 = completely/ No evidence in CR but the has to make a and takes in mind the fifferent target group, adverse effects, pharmacovigilance, costs etc. 2 = partial 3 = no agreement 4 = No evidence and s makes a strong Give examples Title of Cochrane Review could be used Number of Cochrane Review could be used Comment Recommendation included Who found the Cochrane Review Cochrane review relevant to the Cochrane review relevant to the Place to make a comment is there is something extraordinary If the in the is included If the Cochrane Review was included in the or not Title(s) of the Cochrane reviews that could be used Number(s) of Cochrane reviews that could be used. Type the comment 0 = included 1 = excluded 0 = inapplicable/ excluded 1 = Guideline linked the Cochrane Review to the as well (Both). 2 = Guideline linked the Cochrane Review to the but we did not (They). 3 = We linked the Cochrane Review to the but the did not (We). Version

12 Table 3: Cochrane Review data collection Cochrane Review table Arguments Key Cochrane number Numerical number to allocate the Cochrane Numerical number Review. Filename File name of the record. e.g. C0001.csv Cochrane title Identity of the Cochrane Review. Copy the Cochrane Review name from the Cochrane Review. Cochrane disease Disease where the s are made Copy the heading used in the Cochrane Library for. Date of publication Date of Cochrane Review publications Month and year of publication. E.g. Dec-11 Date of first publication Publication date of the first version of the Cochrane Review Copy the date of review first published in the Cochrane Review under history. Number of s Number of s made in the Number of s Cochrane Review. Clear If the is clear or not 0 = (no possible as) no evaluable evidence. Might be a clear but there is no evidence to confirm (e.g. C0282.csv) 1 = soft /partial : made but more evidence necessary to confirm or when may is used in the /effective but benefits have to be weighed against the risk of side effects/clear but more evidence necessary to confirm. 2 = clear neutral s: no significance difference between interventions 3 = clear positive 4 = clear negative 5 = clear (nor positive nor negative) URL For quick access to the Cochrane Review. Copy the URL Comment Place for making a comment if necessary Type the comment Accessed date Accessed date of the Cochrane Review Accessed date of the Cochrane Review. e.g. 03/07/2012 Version

13 Table 4: Cochrane review s data collection Cochrane Review table Arguments Key Cochrane title To identify the Cochrane Review. Copy the Cochrane Review name from the master table of Cochrane reviews. Cochrane number To refer to the Cochrane Review Copy the Cochrane Review number from the master table of Cochrane Reviews Filename File name of the record. e.g. C0001.csv Number of s Number of s made in the Number of s Cochrane Review. Recommendation number Numerical number to allocate the Numerical number. Recommendation Recommendation made in the Cochrane Review Copy the author s conclusions form the Cochrane Review Recommendation included Patient s age Subcategory of patients/disease Moment of therapy Type of intervention See Table 2: Guideline data collection Specific medicine Main group of the medicine Number of the main group of the medicine Dosage Version

14 Table 5: Cochrane Reviews relevant to the Cochrane Reviews and Guidelines linking table Arguments Key Name of To identify the. Copy the name from the master table of s Number of To refer to the Copy the number from the master table of s File name File name of the record. e.g. L0001.csv Number Number of the inserted data e.g. 1 Title of Cochrane Review referred to in the Title of Cochrane Review mentioned in the references Copy the title of the Cochrane Review 0 =inapplicable Number of Cochrane Review referred to in the Number of Cochrane Review mentioned in the references Copy the number of the Cochrane Review 0 =inapplicable Comment Reason for excluding a Cochrane Review/ we did If applicable type the comment Cochrane Review linked to a by the Title of Cochrane Review found by us Number of Cochrane Review found by us Cochrane Review linked to a by us Who found the Cochrane Review not find the Cochrane Review If a Cochrane Review is in agreement with a specific made in the If a Cochrane Review is relevant to a on basis of the name of the or of a made in the If a Cochrane Review is relevant to a on basis of the name of the or of a made in the If a Cochrane Review is relevant to a in the based on that If the Cochrane Review is cited by the or not. 0 =inapplicable 0 = inapplicable (Cochrane Review excluded/withdrawn from publication) 1 = yes 2 = no Copy the title of the Cochrane Review 0 =inapplicable Copy the number of the Cochrane Review 0 =inapplicable 0 = inapplicable (did not find the Cochrane Review) 1 = yes 2 = no 0 = inapplicable 1 = the as well 2 = only the 3 = only we 4 = only the but excluded. E.g. pregnancy/adults only/withdrawn Version

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For

More information

Global Initiative for Asthma (GINA) What s new in GINA 2015?

Global Initiative for Asthma (GINA) What s new in GINA 2015? Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other

More information

educating people and transforming lives worldwide

educating people and transforming lives worldwide Takingaction, educating people and transforming lives worldwide COPD elearning Diploma (Level 5) Module 2012 CONTENTS PAGE UNIT 1: WRITING FOR SUCCESS Writing for Success 2 UNIT 2: INTRODUCTION TO COPD

More information

CONTENTS SECTION 1 SECTION

CONTENTS SECTION 1 SECTION CONTENTS SECTION 1 Foundations of Drug Therapy 1 CHAPTER 1 Introduction to Pharmacology 3 A Message to Students 3 Pharmacology and Drug Therapy 3 Understanding Grouping and Naming of Drugs 4 Prescription

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary

More information

Global Initiative for Asthma (GINA) What s new in GINA 2016?

Global Initiative for Asthma (GINA) What s new in GINA 2016? Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK

Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK Update on bronchiectasis guidelines James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK University of Dundee Bronchiectasis guidelines 2017 2010 2006 2008 2015 2015 Currently valid guidelines

More information

Add on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes

Add on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective

More information

Technology appraisal guidance Published: 24 April 2013 nice.org.uk/guidance/ta278

Technology appraisal guidance Published: 24 April 2013 nice.org.uk/guidance/ta278 Omalizumab for treating severeere persistent allergic asthma Technology appraisal guidance Published: 24 April 2013 nice.org.uk/guidance/ta278 NICE 2018. All rights reserved. Subject to Notice of rights

More information

ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H.

ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H. - 63-3. ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H. We conducted a MEDLINE search of review articles on rhinitis between the years of 1990-1995 and selected articles pertaining to allergic rhinitis. We also

More information

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES: TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY

More information

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017 GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary

More information

COPD Treatable. Preventable.

COPD Treatable. Preventable. My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My

More information

Bronchodilator Delivery and Nebuliser Trials in Adults

Bronchodilator Delivery and Nebuliser Trials in Adults Bronchodilator Delivery and Nebuliser Trials in Adults Acute Management Favour the use of MDI (+/- Spacer) If considering nebuliser Short term treatment Approx. < 3 weeks See optimisation of inhaled bronchodilators

More information

omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd.

omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd. Scottish Medicines Consortium Re-Submission omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd. 8 December 2006 The Scottish Medicines Consortium (SMC)

More information

2. Does the patient have chronic urticaria? Y N

2. Does the patient have chronic urticaria? Y N Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Bronchiolitis: diagnosis and management of bronchiolitis in children. 1.1 Short title Bronchiolitis in children 2 The remit The

More information

A primary care perspective on the new British asthma guideline

A primary care perspective on the new British asthma guideline A primary care perspective on the new British asthma guideline Bronwen Thompson discusses the revisions to the BTS/SIGN guideline with Dr Hilary innock This guideline update 1 is significant. It builds

More information

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma

More information

Protocol Development: The Guiding Light of Any Clinical Study

Protocol Development: The Guiding Light of Any Clinical Study Protocol Development: The Guiding Light of Any Clinical Study Susan G. Fisher, Ph.D. Chair, Department of Clinical Sciences 1 Introduction Importance/ relevance/ gaps in knowledge Specific purpose of the

More information

BNF CHAPTER 3: RESPIRATORY

BNF CHAPTER 3: RESPIRATORY 3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe

More information

Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)

Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University

More information

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Global Initiative for Asthma (GINA) What s new in GINA 2017? Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome

More information

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device 3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose

More information

Medicine Dr. Kawa Lecture 4 - Treatment of asthma :

Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Avoiding allergens. Hyposensitization :Subcutaneous injections of inially very small, but gradually increasing doses of allergens (desensitization or

More information

Guideline for the Diagnosis and Management of COPD

Guideline for the Diagnosis and Management of COPD Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially

More information

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD

More information

Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet

Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet 1 Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet 1 Name of Guideline / Policy/ Procedure MANAGEMENT OF ACUTE PAEDIATRIC ASTHMA Purpose of Procedure/

More information

Chapter 3: Respiratory System (7 th Edition)

Chapter 3: Respiratory System (7 th Edition) Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment

More information

Decramer 2014 a &b [21]

Decramer 2014 a &b [21] Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively

More information

Diagnosis, Treatment and Management of Asthma

Diagnosis, Treatment and Management of Asthma Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

Clinical Practice Guideline: Asthma

Clinical Practice Guideline: Asthma Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator

More information

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking

More information

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing National Institute for Health and Care Excellence Final Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing Evidence review December 2018 Contents Disclaimer The recommendations

More information

CME/CE POSTTEST CME/CE QUESTIONS

CME/CE POSTTEST CME/CE QUESTIONS CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education

More information

XOLAIR (omalizumab) Prior Authorization

XOLAIR (omalizumab) Prior Authorization MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists

More information

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the

More information

Clinical Practice Guideline: Allergic Rhinitis Executive Summary

Clinical Practice Guideline: Allergic Rhinitis Executive Summary Clinical Practice Guideline: Allergic Rhinitis Executive Summary By: Nada Alouda, intern Article provided by: Dr. Amal Bin Hazza Otolaryngology/H&NS Dep. 2018 Quality improvement opportunity Guideline:

More information

QIPP Prescribing Comparators: Description and Specification

QIPP Prescribing Comparators: Description and Specification Prescribing s: Description and Specification This document details the descriptions and specifications for the prescribing comparators. They should be read in conjunction with the National Prescribing

More information

Background. Background. Background 3/14/2014. Conflict of Interest Statement:

Background. Background. Background 3/14/2014. Conflict of Interest Statement: Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest

More information

Public Dissemination

Public Dissemination 1. THE ASTHMA CONDITION 9 18 3 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.

More information

GUIDE LINE SUMMARY THE DIAGNOSIS AND TREATMENT OF ADULT ASTHMA BEST PRACTICE EV I DENCE-BASED KEY MESSAGES. Diagnosis.

GUIDE LINE SUMMARY THE DIAGNOSIS AND TREATMENT OF ADULT ASTHMA BEST PRACTICE EV I DENCE-BASED KEY MESSAGES. Diagnosis. THE DIAGSIS AND TREATMENT OF ADULT ASTHMA The purpose of the guideline is to provide an evidence-based summary of the diagnostic management and treatment options available for asthma in the adult population

More information

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,

More information

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

An Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital

An Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence

More information

Pathology of Asthma Epidemiology

Pathology of Asthma Epidemiology Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

By the end of this lecture physicians will:

By the end of this lecture physicians will: No disclosure By the end of this lecture physicians will: 1. Be able to identify patients who need immune work-up. 2. Be able to recognize the manifestation of food allergies. 3. Be knowledgeable about

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

This is the publisher s version. This version is defined in the NISO recommended practice RP

This is the publisher s version. This version is defined in the NISO recommended practice RP Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,

More information

Setting The setting was the community. The economic study was carried out in New Jersey, USA.

Setting The setting was the community. The economic study was carried out in New Jersey, USA. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy Luskin A, Bukstein D, Kocevar V S, Yin D D Record Status This

More information

Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.

Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section. Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE

More information

SCREENING AND PREVENTION

SCREENING AND PREVENTION These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow

More information

EXACERBATION ASSESSMENT FORM

EXACERBATION ASSESSMENT FORM EXACERBATION ASSESSMENT FORM ID NUMBER: 0a) Form Completion Date... 0b) Staff Code... Administrative Information 1) Date of clinic visit: 2) What type of Event is this?... Participant/HCU-triggered...

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for

More information

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014 GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence

More information

TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines

TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common

More information

EXACERBATION ASSESSMENT FORM

EXACERBATION ASSESSMENT FORM EXACERBATION ASSESSMENT FORM ID NUMBER: VERSION: 1.0 05/27/14 0a) Form Completion Date... 0b) Staff Code... Instructions: This form should be completed when a participant comes to the clinical center for

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR) Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of

More information

Surveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved. Surveillance report 2017 Antenatal and postnatal mental health: clinical management and service guidance (2014) NICE guideline CG192 Surveillance report Published: 8 June 2017 nice.org.uk NICE 2017. All

More information

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Drug Prior Authorization Guideline NUCALA (mepolizumab) Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and

More information

The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons

The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,

More information

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download

More information

Management of URTI s in Children

Management of URTI s in Children Management of URTI s in Children Robin J Green PhD Antibiotics - Dilemmas for General Practitioners Antibiotic overuse = Resistance Delay in antibiotic use = Mortality Patient expectation Employer expectation

More information

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing

More information

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Michael Schatz, MD, MS Allergy Department Kaiser Permanente, San Diego, CA Constructs

More information

Clinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013

Clinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013 1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT

More information

Michael S. Blaiss, MD

Michael S. Blaiss, MD Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine Division of Clinical Immunology and Allergy University of Tennessee Health Science Center Memphis, Tennessee Speaker s Bureau: AstraZeneca,

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Get Healthy Stay Healthy

Get Healthy Stay Healthy Asthma Management WHAT IS ASTHMA? Asthma causes swelling and inflammation in the breathing passages that lead to your lungs. When asthma flares up, the airways tighten and become narrower. This keeps the

More information

Phototherapy in Allergic Rhinitis

Phototherapy in Allergic Rhinitis Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis

More information

Step up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible

Step up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible 12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?

More information

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing National Institute for Health and Care Excellence Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Disclaimer The

More information

Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial Pinnock H, McKenzie L, Price D, Sheikh A

Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial Pinnock H, McKenzie L, Price D, Sheikh A Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial Pinnock H, McKenzie L, Price D, Sheikh A Record Status This is a critical abstract of an economic

More information

National Asthma Educator Certification Board Detailed Content Outline

National Asthma Educator Certification Board Detailed Content Outline I. THE ASTHMA CONDITION 9 20 1 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.

More information

(Asthma) Diagnosis, monitoring and chronic asthma management

(Asthma) Diagnosis, monitoring and chronic asthma management Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic

More information

The child with a troublesome cough. Dr Marco Zampoli Paediatric Pulmonology Red Cross War Memorial Children s Hospital GP Refresher Course 2012

The child with a troublesome cough. Dr Marco Zampoli Paediatric Pulmonology Red Cross War Memorial Children s Hospital GP Refresher Course 2012 The child with a troublesome cough Dr Marco Zampoli Paediatric Pulmonology Red Cross War Memorial Children s Hospital GP Refresher Course 2012 Cough is the most common symptom in children Inability to

More information

This activity is jointly provided by Global Education Group and Educational Awareness Solutions. Copyright 2018.

This activity is jointly provided by Global Education Group and Educational Awareness Solutions. Copyright 2018. Complications Associated with Excessive Mucus Production Secondary bacterial infections Sinusitis Bronchitis Pneumonia Red Flags for Referral Dyspnea (shortness of breath) or wheezing Hemoptysis (coughing

More information

A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy

A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy Executive summary Aims of the review The main aim of the review was to assess the

More information

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date

More information

2. Has the child had a physician s diagnosis of atopic dermatitis or atopic eczema ever?

2. Has the child had a physician s diagnosis of atopic dermatitis or atopic eczema ever? Online Supplement 2: Letter questionnaire RISK FACTORS FOR THE DEVELOPMENT OF ASTHMA 1. Have the child s parents had a history of asthma ever? 2. Has the child had a physician s diagnosis of atopic dermatitis

More information

Title Protocol for the Management of Asthma

Title Protocol for the Management of Asthma Document Control Title Protocol for the Management of Asthma Author Author s job title Professional Lead, Minor Injuries Unit Directorate Emergency Services, Logistics and Resilience Department Version

More information

PCRS-UK briefing document Asthma guidelines. November 2017

PCRS-UK briefing document Asthma guidelines. November 2017 PCRS-UK briefing document Asthma guidelines November 2017 1 1. Background The Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) have been collaborating on producing

More information

Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015

Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation

More information

Symptomatic treatment of the cough inwhooping cough. Dr Pham Thai Son

Symptomatic treatment of the cough inwhooping cough. Dr Pham Thai Son Symptomatic treatment of the cough inwhooping cough (Review) Dr Pham Thai Son 1 Disease Description Pertussis, a cough illness commonly known as whooping cough (100 Day Cough), is caused by the bacterium

More information

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which

More information

The Role of Allergy Testing to Achieve Personalized Treatment Goals for Allergic Rhinitis and Asthma

The Role of Allergy Testing to Achieve Personalized Treatment Goals for Allergic Rhinitis and Asthma Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Diagnostics guidance Published: 2 April 2014 nice.org.uk/guidance/dg12

Diagnostics guidance Published: 2 April 2014 nice.org.uk/guidance/dg12 Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath Diagnostics guidance Published: 2 April 2014 nice.org.uk/guidance/dg12 NICE 2017. All rights reserved.

More information